SEC 13F Intelligence

Managers / Q2 2021 · view latest →

Consonance Capital Management LP

CIK 0001544773 · 1370 AVENUE OF THE AMERICAS, SUITE 3301, NEW YORK, NY, 10019 · 212.660-8062

Reported Value
$831M
Q2 2021
Positions
32
Filings on Record
15
2019–present window
Filed
Aug 16, 2021
original filing

Summary

Consonance Capital Management LP reported $831M in U.S.-listed holdings across 32 positions for Q2 2021.

Its largest position, PTGX, represents 18.6% of the portfolio.

Compared with Q1 2021, the fund opened 8 new positions and exited 11.

Portfolio Metrics

Turnover
+39.9%
vs prior filed quarter
Top-10 Concentration
+82.0%
share of reported value
Largest Position
+18.6%
Protagonist Therapeutics
New / Exited
8 / 11
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q1 ’19: $1.6BQ1 ’19Q2 ’19: $1.4BQ3 ’19: $1.0BQ3 ’19Q4 ’19: $1.6BQ1 ’20: $1.3BQ1 ’20Q2 ’20: $1.7BQ3 ’20: $821MQ3 ’20Q4 ’20: $1.1BQ1 ’21: $938MQ1 ’21Q2 ’21: $831MQ3 ’21: $183MQ3 ’21Q4 ’21: $153MQ1 ’22: $59MQ1 ’22Q2 ’22: $24MQ3 ’22: $7MQ3 ’22filingsflow.com

Portfolio Composition

By security type
Common Stock: 74.8%Other: 16.4%ADR: 8.8%
  • Common Stock · 74.8% · $622M
  • Other · 16.4% · $136M
  • ADR · 8.8% · $73M

Quarter-over-Quarter Changes full breakdown →

vs Q1 2021 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
TNDMTANDEM DIABETES CARE INCNEW+979.2K979.2K+$95M$95M
SRPTSAREPTA THERAPEUTICS INCNEW+409.3K409.3K+$32M$32M
MEDICUS SCIENCES ACQUISITIONNEW+300.0K300.0K+$3M$3M
CAREMAX INCNEW+213.0K213.0K+$3M$3M
PANACEA ACQUISITION CORP IINEW+200.0K200.0K+$2M$2M
TKNOALPHA TEKNOVA INCNEW+75.0K75.0K+$2M$2M
CAREMAX INCNEW+46.0K46.0K+$217,000$217,000
MEDICUS SCIENCES ACQUISITIONNEW+33.3K33.3K+$34,000$34,000

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2021

30 positions (from 32 filing rows — )
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1PTGXPROTAGONIST THERAPEUTICS INChistory →COM18.62%$155M3.45M
2SPRINGWORKS THERAPEUTICS INCCOM11.89%$99M1.20M
3TNDMTANDEM DIABETES CARE INChistory →COM NEW11.48%$95M979.2K
4GMEDGLOBUS MED INChistory →CL A10.12%$84M1.08M
5LEGNLEGEND BIOTECH CORPhistory →SPONSORED ADS8.14%$68M1.65M
6VERASTEM INCCOM6.66%$55M13.60M
7KROSKEROS THERAPEUTICS INChistory →COM4.54%$38M887.9K
8SRPTSAREPTA THERAPEUTICS INChistory →COM3.83%$32M409.3K
9UTHRUNITED THERAPEUTICS CORP DELhistory →COM3.43%$29M159.1K
10AFFIMED N VCOM3.25%$27M3.18M
11GAMIDA CELL LTDSHS2.21%$18M2.86M
12CASI PHARMACEUTICALS INCCOM1.93%$16M10.32M
13CFMSCONFORMIS INChistory →COM1.76%$15M12.74M
14DECIPHERA PHARMACEUTICALS INCOM1.71%$14M388.2K
15NKTXNKARTA INChistory →COM1.68%$14M439.9K
16INFIQINFINITY PHARMACEUTICALS INChistory →COM1.36%$11M3.77M
17ADICET BIO INCCOM1.27%$11M1.03M
18CONSONANCE HFW ACQUISITION CUNIT 99/99/99991.25%$10M1.00M
19SIO GENE THERAPIES INCCOMMON0.98%$8M2.97M
20SLNSILENCE THERAPEUTICS PLCADS0.70%$6M222.2K
21CELLECTAR BIOSCIENCES INCCOM PAR0.56%$5M3.91M
22RESEARCH ALLIANCE CORP IICOM CL A0.36%$3M300.0K
23JIYA ACQUISITION CORPCOM CL A0.36%$3M300.0K
24CAREMAX INCCOM CL A · *W EXP 06/08/2020.36%$3M259.0K
25MEDICUS SCIENCES ACQUISITIONCL A SHS · *W EXP 02/12/2020.35%$3M333.3K
26ARYA SCIENCES ACQU CORP IVCL A0.32%$3M250.0K
27BCTG ACQUISITION CORPCOM0.25%$2M180.0K
28PANACEA ACQUISITION CORP IICL A SHS0.24%$2M200.0K
29TKNOALPHA TEKNOVA INCCOM0.21%$2M75.0K
30HELIX ACQUISITION CORPCOM CL A0.19%$2M150.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q3 2022$7M2Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$24M7Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$59M8May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$153M15Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$183M17Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$831M32Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$938M35May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$1.1B38Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$821M27Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$1.7B32Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$1.3B31May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$1.6B35Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$1.0B30Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$1.4B30Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$1.6B26May 15, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.